Trial Profile
Survey of European Lung cancer Evaluating Choice of Treatment and Tolerability In observed second-line Non-small cell lung cancer
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2007
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SELECTTION
- 06 Sep 2007 New trial record.